Your session is about to expire
← Back to Search
Doxorubicin Microneedles for Basal Cell Carcinoma
Study Summary
This trial is designed to study the effect of P-MNA (a dissolvable microneedle array) on healthy human volunteers, with the goal of determining how different factors affect the rate and extent of microneedle array dissolution. The trial will be conducted in two parts. In Part II, subjects will be randomized to one of four dose groups to receive either a placebo or a specified amount of doxorubicin in a tip-loaded, dissolvable microneedle array.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- Less than 25% of my target lesion was removed during biopsy.I have a genetic condition that causes skin cancer.I have no significant health issues apart from my current condition.My skin cancer lesion fits the size range given.I have had surgery to remove the lesion that will be treated in this study.I am over 18 and in good health.My cancer has spread to other parts of my body.I have responded well to doxorubicin or carboxymethyl cellulose treatment before.My skin cancer is in a spot where cutting it out would look bad or isn't wanted.I am on medication that weakens my immune system due to another illness.I do not have any severe illnesses that are not under control.I have a skin condition near my basal cell carcinoma.I am currently taking blood thinners.I can avoid sunlight on the target lesion for the study duration.I haven't used any skin treatments on the cancer area in the last 6 weeks.I have cancer, but it's not one of the excluded types.I am a woman who is either not of childbearing potential, has a negative pregnancy test, or uses contraception.I have recently had treatment on the area affected by basal cell carcinoma.I am a man and will follow the required birth control methods if my partner can have children.I have a condition or received treatment in the last 3 months that could affect my healing.My basal cell carcinoma has come back at the same spot.I am not pregnant or breastfeeding.My skin cancer was confirmed by a biopsy.
- Group 1: Doxorubicin-containing MNA - 100 µg
- Group 2: Placebo MNA for Training
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participants involved in this clinical research?
"Affirmative. As outlined on clinicaltrials.gov, this medical trial first opened for recruitment on September 24th 2021 and was last updated August 10th 2022 - actively seeking 25 participants from 2 distinct locations."
Is the age criterion for this experiment limited to individuals under 55 years of age?
"Those who apply for this trial must be between 18 to 75 years old. There are 95 studies available for minors and 325 research opportunities designated for seniors above the age of 65."
Is there an ongoing recruitment of participants for this clinical trial?
"Clinicaltrials.gov attests that this medical research is currently searching for participants, having been initially posted on September 24th 2021 and most recently amended on August 10th 2022."
What maladies have been demonstrated to be remedied by Placebo MNA for Training?
"Placebo MNA for Training is habitually utilized to treat lymphoma and Hodgkin's, as well as other diseases such as carcinoma, bronchogenic, neuroblastoma (NB), and Sezary Syndrome."
Does this research endeavor mark a novel application of methodology?
"Since 1997, Placebo MNA for Training has been the subject of clinical investigation. Alfacell's first trial concerning this medication took place that same year and involved 300 participants. After receiving Phase 3 approval, there are currently 360 trials underway in 66 different nations and 1941 cities worldwide."
Are there any prior studies which have utilized Placebo MNA for Training?
"The Placebo MNA for Training protocol was first implemented at Spectrum Health Hospital - Butterworth Campus in 1997. Since then, 677 trials have been completed and 360 are currently on-going with many based out of West Palm Beach, Florida."
Do I meet the qualifications necessary to participate in this medical experiment?
"This clinical trial is open to 25 men and women aged 18-75 with a diagnosis of basal cell carcinoma. In order to qualify, subjects must also fulfill the following criteria: general good health as assessed by the investigator, minimum granulocytes and platelets counts, serum creatinine below twice the upper limit of normal (ULN), AST, ALT, LDH and alkaline phosphatase all at or lower than three times ULN; no other clinically significant abnormal findings in medical history or physical examination; willingness to adhere to instructions from research team and sign informed consent form prior to study procedures; BCC confirmed histologically via"
Share this study with friends
Copy Link
Messenger